Abstract: A method to produce metallic beryllium spheres with high sphericity in a large quantity efficiently at a low cost is provided herein. The method of continuously producing metal beryllium spheres comprises the steps of: collecting granulated beryllium spheres produced by charging beryllium powder into a rotary kiln; classifying the collected beryllium spheres by particle size with an automatic sieve; and crushing particles of beryllium spheres of non-target diameters and mixing them with the raw material beryllium powder for reuse. The rotary kiln has a core tube the inner surface of which is coated with beryllium oxide by sintering the slurry coating of beryllium hydroxide applied after alkaline silica treatment.

Abstract: To produce metallic beryllium spheres with high sphericity in a large quantity efficiently at a low cost by a simple method. The continuously producing method of metal beryllium spheres, comprising the steps of: collecting granulated beryllium spheres produced b by charging beryllium powder into a rotary kiln; classifying the collected beryllium spheres by particle size with an automatic sieve; and crushing particles of beryllium spheres of non-target diameters and mixing them with the raw material beryllium powder for reuse. The rotary kiln has a core tube the inner surface of which is coated with beryllium oxide by sintering the slurry coating of beryllium hydroxide applied after alkaline silica treatment.

Abstract: Methods of making compounds of Formula I are disclosed:

Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Abstract: Methods of making compounds of Formula I are disclosed:

Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Abstract: Methods of making compounds of Formula I are disclosed:

Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

Abstract: The present disclosure provides solid forms, including a salt or co-crystal, of Compound I: which exhibits Acetyl-CoA carboxylase (“ACC”) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.

Abstract: Methods of making compounds of Formula I are disclosed:

Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

Abstract: Methods of making compounds of Formula I are disclosed:

Abstract: Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetraGalNAc ligands of Formula (I), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.

Abstract: This invention relates to a process for preparing optically active ?-amino acid substrates which are used to make potent lethal factor (LF) inhibitors for the treatment of anthrax. This invention further relates to a process for synthesis of potent LF-inhibitors for the treatment of anthrax. Specifically, the invention concerns a novel, high-yielding and highly enantioselective asymmetric hydrogenation reaction of a tetrasubstituted ene-sulfonamide acid or ester.

Abstract: This invention relates to a process for preparing optically active ?-amino acid substrates which are used to make potent lethal factor (LF) inhibitors for the treatment of anthrax. This invention further relates to a process for synthesis of potent LF-inhibitors for the treatment of anthrax. Specifically, the invention concerns a novel, high-yielding and highly enantioselective asymmetric hydrogenation reaction of a tetrasubstituted ene-sulfonamide acid or ester.

Abstract: The present invention is concerned with a process for the preparation of trifluorophenylacetic acids using a Grignard reagent and an allylating agent, such as allyl bromide.

Abstract: The present invention is concerned with a process for the preparation of trifluorophenylacetic acids using a Grignard reagent and an allylating agent, such as allyl bromide.

Abstract: The present invention addresses a process for the preparation of 2,4,5-trifluorophenylacetic acid using a Cu(I) salt as a catalyst.